
Catabasis Pharmaceuticals, Inc. Revenue | CATB
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Catabasis Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 500 K | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 500 K | 500 K | 500 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Pharming Group N.V.
PHAR
|
186 M | $ 12.48 | 3.51 % | $ 8.6 B | ||
|
Capricor Therapeutics
CAPR
|
22.3 M | $ 8.04 | -4.4 % | $ 374 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
720 M | $ 29.66 | 1.91 % | $ 1.39 B | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
326 B | $ 14.98 | 1.28 % | $ 12.5 B | ||
|
China Biologic Products Holdings, Inc.
CBPO
|
524 M | - | 1.68 % | $ 4.65 B | ||
|
Regeneron Pharmaceuticals
REGN
|
14.3 B | $ 945.14 | -1.32 % | $ 98.9 B | ||
|
Aquestive Therapeutics
AQST
|
44.5 M | $ 3.78 | 2.16 % | $ 404 M | ||
|
Jaguar Health
JAGX
|
11.5 M | $ 0.35 | -8.69 % | $ 816 K | ||
|
Arvinas
ARVN
|
263 M | $ 6.77 | -0.73 % | $ 480 M | ||
|
Cerus Corporation
CERS
|
234 M | $ 1.95 | 2.63 % | $ 372 M | ||
|
Beam Therapeutics
BEAM
|
140 M | $ 21.03 | 1.82 % | $ 2.08 B | ||
|
Inhibrx
INBX
|
1.8 M | $ 68.87 | -7.16 % | $ 3.25 B | ||
|
Royalty Pharma plc
RPRX
|
2.38 B | $ 68.76 | 0.12 % | $ 29.6 B | ||
|
Entera Bio Ltd.
ENTX
|
42 K | $ 3.24 | 8.0 % | $ 150 M | ||
|
Revolution Medicines
RVMD
|
11.6 M | $ 159.7 | -1.84 % | $ 30.4 B | ||
|
Flexion Therapeutics, Inc.
FLXN
|
85.6 M | - | - | $ 459 M | ||
|
Legend Biotech Corporation
LEGN
|
627 M | $ 16.25 | 0.87 % | $ 5.99 B | ||
|
CytomX Therapeutics
CTMX
|
76.2 M | $ 1.91 | -1.55 % | $ 263 M | ||
|
Krystal Biotech
KRYS
|
389 M | $ 314.77 | 5.43 % | $ 9.11 B | ||
|
Kura Oncology
KURA
|
67.5 M | $ 7.34 | -2.07 % | $ 644 M | ||
|
Inhibikase Therapeutics
IKT
|
261 K | $ 1.39 | 0.36 % | $ 137 M | ||
|
Phathom Pharmaceuticals
PHAT
|
175 M | $ 5.31 | -3.45 % | $ 387 M | ||
|
Heron Therapeutics
HRTX
|
155 M | $ 0.27 | -3.26 % | $ 45 M | ||
|
Inovio Pharmaceuticals
INO
|
65.3 K | $ 1.69 | 3.37 % | $ 79.2 M | ||
|
SIGA Technologies
SIGA
|
94.6 M | $ 2.81 | 2.75 % | $ 201 M | ||
|
Aytu BioScience
AYTU
|
57.6 M | $ 2.66 | -0.19 % | $ 32.8 M | ||
|
Heat Biologics, Inc.
HTBX
|
2.95 M | - | -5.76 % | $ 99.8 M | ||
|
Innoviva
INVA
|
411 M | $ 18.36 | 0.3 % | $ 1.24 B | ||
|
BioCardia
BCDA
|
58 K | $ 0.77 | -2.06 % | $ 5.13 M | ||
|
Kindred Biosciences, Inc.
KIN
|
42.2 M | - | 0.11 % | $ 419 M | ||
|
Syndax Pharmaceuticals
SNDX
|
172 M | $ 8.55 | -7.07 % | $ 741 M | ||
|
Alterity Therapeutics Limited
ATHE
|
109 K | $ 1.72 | -7.77 % | $ 11 B | ||
|
Shineco, Inc.
TYHT
|
23.7 M | - | -3.90 % | $ 97.2 M | ||
|
Oramed Pharmaceuticals
ORMP
|
2 M | $ 3.9 | 0.78 % | $ 161 M | ||
|
Certara
CERT
|
419 M | $ 11.25 | 1.72 % | $ 1.8 B | ||
|
PainReform Ltd.
PRFX
|
17 K | $ 0.63 | -4.8 % | $ 408 K | ||
|
Anika Therapeutics
ANIK
|
113 M | $ 13.74 | 6.89 % | $ 197 M | ||
|
Prothena Corporation plc
PRTA
|
9.68 M | $ 8.38 | 1.39 % | $ 451 M | ||
|
Processa Pharmaceuticals
PCSA
|
5 K | $ 1.7 | -2.3 % | $ 2.23 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
761 M | $ 67.94 | -3.04 % | $ 7.06 B | ||
|
Progenity, Inc.
PROG
|
74.3 M | - | -3.47 % | $ 164 M | ||
|
China SXT Pharmaceuticals
SXTC
|
1.14 M | $ 2.84 | -0.7 % | $ 1.93 M |